Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Pharma Industry News ImmunogenX enrolls patients for Solutions for Celiac trial of Latiglutenase ImmunogenX, a subsidiary of Immunogenics, has started enrollment of patients for a phase 2b clinical trial to evaluate… bypharmanewsdailyFebruary 14, 2020
